Aditya Bardia, a breast medical oncologist and physician scientist who specializes in developing novel targeted and personalized therapies, joined the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center, where he will assume several leadership roles across the institution.
The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
